|
This follow-up report is submitted to fda in accord with applicable regulations ¿ and as indicated by terumo cardiovascular systems in the initial report submitted to the fda on september 16, 2019.Upon further investigation of the reported event, the following information is new and/or changed: d1 (suspect medical device - updated brand name).D4 (additional device information - updated model number and unique identifier (udi).Number, added exp date).G4 (date received by manufacturer).G7 (indication that this is a follow-up report).H2 (follow-up due to correction and additional information).H4 (device manufacture date).H6 (identification of evaluation codes 11, 3331, 4114, 3221, 4315).Method code #1: 11 - testing of device from same lot/batch retained by manufacturer.Method code #2: 3331 - analysis of production records.Method code #3: 4114 - device not returned.Results code: 3221 - no findings available.Conclusions code: 4315 - cause not established.The affected samples were not returned for evaluation so a thorough investigation could not be conducted.Additionally, pictures were not provided to show the tears in the packaging.A representative retention sample was reviewed and found to have the sterile packaging to be completely intact.All capiox units are 100% visually inspected at several points in the production process.As the product fits into the carton tightly, to minimize any damage during shipping and handling, it is likely that the observed damage was caused by a stress placed on the packaging.How or when this occurred was not able to be determined.All available information has been placed on file in quality management for appropriate tracking, trending, and follow-up.
|